Leaflet IGZELYM 60mg film-coated tablets

Product code:
W68809001
Quantity:
14
Indicated for:
prevention of atherothrombotic events
Route of administration:
oral
Substance:
ticagrelor (antiplatelet agent)
ATC
B01AC24 — Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin

Precautions:

Major drug interactions

This medicine may have important interactions with other medicines.

Bleeding risk

This medicine may increase the risk of bleeding.

Ticagrelor is an antiplatelet medication used to prevent thrombotic events such as myocardial infarction or stroke in patients with acute coronary syndromes or a history of myocardial infarction. It works by reversibly inhibiting P2Y12 receptors on platelets, preventing platelet aggregation.

The medication is taken orally, usually twice daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and not discontinue treatment without consulting their doctor.

Patients should be monitored for potential side effects, such as bleeding, shortness of breath, or dizziness. It is important to inform the doctor of any unusual symptoms or the use of other medications.

Common side effects include bleeding, shortness of breath, and dizziness. In rare cases, severe reactions such as major hemorrhages or bradycardia may occur. Patients should be informed of these risks before starting treatment.

General data about IGZELYM 60mg

Substance:
ticagrelor
Date of latest medicines list:
01-06-2022
Product code:
W68809001
Concentration:
60mg
Pharmaceutical form:
film-coated tablets
Quantity:
14
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
PHAROS MT LTD - MALTA
Holder:
VIATRIS LIMITED - IRLANDA
Number:
13810/2021/01
Shelf life:
2 years

Concentrations available for ticagrelor

  • 60mg
  • 90mg